# CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

> **NCT03312205** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Leukemia
- Lymphoma
- Multiple Myeloma of Bone (Diagnosis)

## Interventions

- **BIOLOGICAL:** Autologous CAR-T cells

## Key facts

- **NCT ID:** NCT03312205
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-29
- **Primary completion:** 2019-08-29
- **Final completion:** 2023-08-29
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312205, "CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03312205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*